Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma
YE Rui
ZHAO Zhi-fei
GAO Ling-ling
WU Xuan
ZHANG Xin-yue
QIU Luan
LI Jian-xiong
Abstract：Objective: To evaluate the efifcacy and toxicity of bevacizumab combination with cisplatin (DDP) and helical tomotherapy (TOMO) treatment in locally advanced nasopharyngeal carcinoma.Methods: Thirty patients with histologically conifrmed stageⅢ–Ⅳ (without distant metastasis) nasopharyngeal carcinoma were recruited with strict eligibility requirements and exclusion criteria from December 2014 to October 2015. Bevacizumab 5 mg·kg-1, 80 mg·m-2 DDP and 67.5 Gy/33 F radiotherapy (TOMO) was given accord ing to the standard treatment protocols.Results:After 3 months, 24 complete responses (80%) and six partial responses (20%) were observed in our research. Twenty-four patients (80%) experienced oropharyngeal mucositis, and 26% patients experienced weight loss caused by pharyngeal pain and dysphagia caused by oropharyngeal mucositis.Conclusion: Bevacizumab plus DDP and TOMO in treatment of locally advanced nasopha ryngeal carcinoma can increase curative effects with low side effects and toxicities.
Keywords：BevacizumabCisplatinHelical tomotherapy (TOMO)Nasopharyngeal carcinoma
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 133-136,137 )